Rigor Reviewed

Rigor-Reviewed Manuscript

Isatuximab, carfilzomib, lenalidomide and dexamethasone in newly diagnosed multiple myeloma: a randomized phase 3 trial.

Name: Αlpha¹ Rigor Record — Isatuximab, carfilzomib, lenalidomide and dexamethasone in newly diagnosed multiple myeloma: a randomized phase 3 trial.
Item: Isatuximab, carfilzomib, lenalidomide and dexamethasone in newly diagnosed multiple myeloma: a randomized phase 3 trial.
Rating: 94
Author: Αlpha¹

Gay F, Roeloffzen W, Dimopoulos MA, Rosiñol L, van der Klift M, Mina R, Oriol A, Katodritou E, Wu KL, Rodríguez Otero P, Hájek R, Antonioli E, van Duin M, D'Agostino M, Martínez-López J, van Leeuwen-Segarceanu EM, Zamagni E, van de Donk NWCJ, Weisel KC, Pour L, Radocha J, Belotti A, Schjesvold F, Bladé J, Einsele H, Sonneveld P, Boccadoro M, Broijl A

Paper source

Read full text (PMC)

Embed this Rigor badge

Αlpha¹ Rigor Review — 2.25★ (Weak), 0 critical, 2 high issues for “Isatuximab, carfilzomib, lenalidomide and dexamethasone in newly diagnosed multiple myeloma: a randomized phase 3 trial.”

Links back to this Rigor Record.

Αlpha¹ Editorial

This rigor review was examined and confirmed by Αlpha¹ Editorial · August 15, 2026

Αlpha¹ Rigor Review

Rigor Reviewed

2.25 / 5

Weak — serious problems found

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern ×3−1.5★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
ClaimsTreatment effect not shown to be clinically meaningful−0.5★
ReportingData & code availability partially met−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Problems surfaced6 types

Numerical inconsistencies1

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Internal contradictions in the reported numbersAssessed

Overstated conclusions3

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Efficacy rests on an unvalidated surrogate endpointAssessed
Treatment effect not shown to be clinically meaningfulAssessed
Conclusions only partially backed by the presented evidenceAssessed

Data authenticity concerns1

An adversarial read for patterns associated with data that may not be genuine: results that look too clean, implausibly large effects, duplicated data or images, and methods that do not match the results reported.

Other integrity concernAssessed

Reporting gaps1

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Data/code availability incompleteAssessed

This Αlpha¹ Rigor Review uses AI Rigor Reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a well-conducted randomized phase 3 trial with a clear scientific premise, rigorous design, and transparent reporting. The main weakness is the data/code availability statement, which is vague and lacks a formal access mechanism, and the absence of a code-sharing statement. Minor copyedit issues include inconsistent superscript formatting and an unclear discontinuation count.

Both reviewers classified the study as interventional; no disagreement. The evaluation covered all eight dimensions; bench-resource criteria (antibodies, cell lines, mycoplasma) were not applicable for this drug trial. The statistics verification recomputed 10 reported tests consistently, but this covers only a subset of tests; the paper's statistics should not be considered fully verified beyond those checks.

8 major claims checked against the paper's own evidence: 2 only partially supported (evidence backs part of the claim; gaps or caveats remain); the rest adequately supported.

Premise concern: surrogate not validated for clinical benefit; effect size not shown to be clinically meaningful.

Recomputed 10 tests: 10 consistent, 0 inconsistent; 6 recomputed directly from the reported test statistics, 4 via agent-written checks.

3 integrity concerns flagged (0 high).

Reporting

Eight Dimensions7 pass · 1 warn

The introduction cites multiple prior studies (FORTE, MIDAS, GMMG-CONCEPT) and explains the rationale for comparing Isa-KRd vs KRd, noting the lack of randomized trials for this quadruplet. Limitations of prior research (e.g., single-arm studies) are acknowledged, and the trial aims to address this gap. The premise is well-supported.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a clear scientific premise by citing prior research on carfilzomib, isatuximab, and MRD as an endpoint, and provides a logical rationale for the trial.

Evidence

direct quote[Introduction, paragraph 1-3]

“In the phase 2 UNITO-MM-01/FORTE trial, carfilzomib–lenalidomide–dexamethasone (KRd) plus ASCT resulted in high rates of pre-maintenance measurable residual disease (MRD) negativity (sensitivity of 10 −5 , 62%) and median progression-free survival (PFS; 99 months)”